Population pharmacokinetic modelling and simulation of 5-fluorouracil incorporating a circadian rhythm in rats

References

• Bressolle F, Joulia JM, Pinguet F, et al. (1999). Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 44:295–302
   PubMed Web of Science ®Google Scholar
• Buchel B, Rhyn P, Schurch S, et al. (2013). LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. Biomed Chromatogr 27:7–16
   PubMed Web of Science ®Google Scholar
• Capitain O, Asevoaia A, Boisdron-Celle M, et al. (2012). Individual fluorouracil dose adjustment in FOLFOX base on pharmacokinetic follow-up compared with conventional bodyarea-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer 11:263–7
   PubMed Web of Science ®Google Scholar
• Fleming GF, Schumm P, Friberg G, et al. (2015). Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer 15:69
   PubMed Web of Science ®Google Scholar
• Fuse E, Takai K, Okuno K, et al. (1996). Hepatic extraction ratio of 5-fluorouracil in rats. Dose dependence and effect of uracil and interleukin-2. Biochem Pharmacol 52:561–8
   PubMed Web of Science ®Google Scholar
• Gamelin E, Delva R, Jacob J, et al. (2008). Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26:2099–105
   PubMed Web of Science ®Google Scholar
• Harris BE, Song RL, He YJ, et al. (1988). Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy. Biochem Pharmacol 37:4759–62
   PubMed Web of Science ®Google Scholar
• Harris BE, Song R, Soong SJ, et al. (1990). Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197–201
   PubMed Web of Science ®Google Scholar
• Heggie GD, Sommadossi JP, Cross DS, et al. (1987). Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203–6
   PubMed Web of Science ®Google Scholar
• Hu K, Scheer FA, Buijs RM, et al. (2008). The circadian pacemaker generates similar circadian rhythms in the fractal structure of heart rate in humans and rats. Cardiovasc Res 80:62–8
   PubMed Web of Science ®Google Scholar
• Huisman SA, Oklejewicz M, Ahmadi AR, et al. (2015). Colorectal liver metastases with a disrupted circadian rhythm phase shift the peripheral clock in liver and kidney. Int J Cancer 136:1024–32
   PubMed Web of Science ®Google Scholar
• Ishikura S, Nihei K, Ohtsu A, et al. (2003). Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 21:2697–702
   PubMed Web of Science ®Google Scholar
• Jarugula VR, Lam SS, Boudinot FD. (1997). Nonlinear pharmacokinetics of 5-fluorouracil in rats. J Pharm Sci 86:756–8
   PubMed Web of Science ®Google Scholar
• Jiang H, Lu J, Ji J. (2004). Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol 141:616–23
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Ito Y, Hayakawa T, et al. (2015). Semi-physiological pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for thrombocytopenia in rats. Xenobiotica 45:19–28
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Ito Y, Hayakawa T, et al. (2014a). Semi-physiological pharmacokinetic-pharmacodynamic modeling and simulation of 5-fluorouracil for the whole time course of alterations in leukocyte, neutrophil and lymphocyte counts in rats. Xenobiotica 44:804–18
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Ito Y, Hayakawa T, et al. (2014b). Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats. J Pharmacol Toxicol Methods 70:134–44
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Ito Y, Okada K, et al. (2013a). Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer. J Pharm Sci 102:2056–67
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Ito Y, Okada K, et al. (2013b). Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine induced colorectal cancer model rats. Eur J Drug Metab Pharmacokinet 38:171–81
   PubMed Web of Science ®Google Scholar
• Kochi M, Akiyama Y, Aoki T, et al. (2013). FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. Cancer Chemother Pharmacol 72:1097–102
   PubMed Web of Science ®Google Scholar
• Konings IR, Sleijfer S, Mathijssen RH, et al. (2011). Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. Cancer Chemother Pharmacol 67:1055–62
   PubMed Web of Science ®Google Scholar
• Kumekawa Y, Kaneko K, Ito H, et al. (2006). Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol 41:425–32
   PubMed Web of Science ®Google Scholar
• Kuwahara A, Yamamori M, Nishiguchi K, et al. (2010). Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma. Int J Med Sci 7:48–54
   PubMedGoogle Scholar
• Lévi F, Zidani R, Misset JL. (1997). Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350:681–6
   PubMed Web of Science ®Google Scholar
• Levi F, Schibler U. (2007). Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 47:593–628
   PubMed Web of Science ®Google Scholar
• Li XM, Mohammad-Djafari A, Dumitru M, et al. (2013). A circadian clock transcription model for the personalization of cancer chronotherapy. Cancer Res 73:7176–88
   PubMed Web of Science ®Google Scholar
• Metzger G, Massari C, Etienne MC, et al. (1994). Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. Clin Pharmacol Ther 56:190–201
   PubMed Web of Science ®Google Scholar
• Milano G, Etienne MC, Renee N, et al. (1994). Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12:1291–5
   PubMed Web of Science ®Google Scholar
• Nelson W, Tong YL, Lee JK, et al. (1979). Methods for cosinorrhythmometry. Chronobiologia 6:305–23
   PubMedGoogle Scholar
• Noguchi C, Miyata H, Sato Y, et al. (2011). Evaluation of bone toxicity in various bones of aged rats. J Toxicol Pathol 24:41–8
   PubMed Web of Science ®Google Scholar
• Petit E, Milano G, Lévi F, et al. (1988). Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 48:1676–9
   PubMed Web of Science ®Google Scholar
• Porsin B, Formento JL, Filipski E, et al. (2003). Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression. Eur J Cancer 39:822-8
   Google Scholar
• Sabath E, Salgado-Delgado R, Guerrero-Vargas NN, et al. (2014). Food entrains clock genes but not metabolic genes in the liver of suprachiasmatic nucleus lesioned rats. FEBS Lett 588:3104–10
   PubMed Web of Science ®Google Scholar
• Saif MW, Choma A, Salamone SJ, et al. (2009). Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 101:1543–52
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Yamamori M, Kuwahara A, et al. (2009). Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Adv Drug Deliv Rev 61:388–401
   PubMed Web of Science ®Google Scholar
• Tahara M, Ohtsu A, Hironaka S, et al. (2005). Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 35:316–323
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB, Maring JG. (2013). Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients. Pharmacogenomics, 14:799–811
   PubMed Web of Science ®Google Scholar
• Zhang R, Lu Z, Liu T, et al. (1993). Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res 53:2816–22
   PubMed Web of Science ®Google Scholar